Multiple sclerosis
- PMID: 11818475
- DOI: 10.1146/annurev.med.53.082901.103909
Multiple sclerosis
Abstract
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system (CNS). Diagnosis rests upon identifying typical clinical symptoms and interpreting supportive laboratory and radiological investigations. The etiology is unknown; however, strong evidence suggests that MS is an autoimmune disease directed against CNS myelin or oligodendrocytes. Genetic factors are important in the development of MS. Contributing environmental determinants (possibly including infectious agents) appear important but remain unidentified. Both cell-mediated and humorally mediated immune mechanisms contribute to pathological injury. Axonal damage occurs in addition to demyelination and may be the cause of later permanent disability. Distinct pathological subtypes may differentiate among patients with MS. Treatment is directed at acute attacks (with corticosteroids) and reduction of attack frequency (primarily with type-1 beta interferons and glatiramer acetate). Research into the causes and treatments of MS has expanded our knowledge of this disease and promises improved care for MS patients in the future.
Similar articles
-
[Recent therapeutic strategy for multiple sclerosis].Rinsho Shinkeigaku. 2001 Dec;41(12):1214-7. Rinsho Shinkeigaku. 2001. PMID: 12235841 Review. Japanese.
-
Neuronal injury in chronic CNS inflammation.Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Best Pract Res Clin Anaesthesiol. 2010. PMID: 21619866 Review.
-
[Therapy of multiple sclerosis].Neuropsychopharmacol Hung. 2009 Mar;11(1):23-6. Neuropsychopharmacol Hung. 2009. PMID: 19731815 Review. Hungarian.
-
Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies.J Neurosci Nurs. 2013 Dec;45(6 Suppl 1):S14-23. doi: 10.1097/JNN.0000000000000020. J Neurosci Nurs. 2013. PMID: 24217187 Review.
-
Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.Curr Opin Ophthalmol. 2009 Nov;20(6):476-81. doi: 10.1097/ICU.0b013e3283319155. Curr Opin Ophthalmol. 2009. PMID: 19816177 Review.
Cited by
-
Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis.Medicine (Baltimore). 2016 Sep;95(36):e4782. doi: 10.1097/MD.0000000000004782. Medicine (Baltimore). 2016. PMID: 27603381 Free PMC article.
-
Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?J Neuroimmune Pharmacol. 2013 Mar;8(1):163-79. doi: 10.1007/s11481-012-9410-z. Epub 2012 Oct 17. J Neuroimmune Pharmacol. 2013. PMID: 23074017 Review.
-
Mechanisms regulating regional localization of inflammation during CNS autoimmunity.Immunol Rev. 2012 Jul;248(1):205-15. doi: 10.1111/j.1600-065X.2012.01126.x. Immunol Rev. 2012. PMID: 22725963 Free PMC article. Review.
-
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria.Rev Neurol. 2023 Nov 30;77(s04):S1-S7. doi: 10.33588/rn.77s04.2023213. Rev Neurol. 2023. PMID: 38018696 Free PMC article. English, Spanish.
-
Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617748845. doi: 10.1177/1756285617748845. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29399052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical